RECRUITINGINTERVENTIONAL
Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients
About This Trial
This study aims to find out whether certain molecules in the blood, called microRNAs, are linked to how often and how severely people develop nerve damage from chemotherapy. The investigators will look at patients receiving cancer drugs known to affect the nerves, such as paclitaxel (used for lung cancer) and oxaliplatin (used for colorectal cancer).
Who May Be Eligible (Plain English)
Who May Qualify:
- Patient treated for colorectal cancer and scheduled to receive oxaliplatin-based adjuvant chemotherapy for at least 6 cycles, or
- Patient treated for lung cancer and scheduled to receive paclitaxel-based chemotherapy for at least 4 cycles.
Who Should NOT Join This Trial:
- Neurodegenerative disease (e.g., Parkinson's, Alzheimer's, etc.),
- History of stroke,
- Pre-existing neuropathy (QLQ-CIPN20 sensory score ≥ 15/100),
- Pain (NRS ≥ 4/10),
- Pregnant or breastfeeding women,
- Patients under guardianship, curatorship, deprived of liberty, or under legal protection
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patient treated for colorectal cancer and scheduled to receive oxaliplatin-based adjuvant chemotherapy for at least 6 cycles, or
* Patient treated for lung cancer and scheduled to receive paclitaxel-based chemotherapy for at least 4 cycles.
Exclusion Criteria:
* Neurodegenerative disease (e.g., Parkinson's, Alzheimer's, etc.),
* History of stroke,
* Pre-existing neuropathy (QLQ-CIPN20 sensory score ≥ 15/100),
* Pain (NRS ≥ 4/10),
* Pregnant or breastfeeding women,
* Patients under guardianship, curatorship, deprived of liberty, or under legal protection
Treatments Being Tested
DIAGNOSTIC_TEST
Assessment of blood concentrations of microRNAs
day 1, day 43, and day 155.
OTHER
Chemotherapy-induced peripheral neuropathy (CIPN) - grade
day 1, day 43, and day 155.
OTHER
Pain assessement
day 1, day 43, and day 155.
DIAGNOSTIC_TEST
Assessment of blood concentrations of neurofilament light chain
day 1, day 43, and day 155.
OTHER
Neuropathic pain assessment
day 1, day 43, and day 155.
OTHER
Chemotherapy-induced peripheral neuropathy (CIPN) - severity
day 1, day 43, and day 155.
Locations (1)
CHU Clermont-Ferrand
Clermont-Ferrand, France